Severe Asthma

SAN FRANCISCO — In patients with uncontrolled moderate to severe asthma, a fixed-dose combination of albuterol and budesonide used as an as-needed rescue medication lowered risk for severe asthma exacerbations compared with albuterol alone.

Although infrequent, high use of short-acting beta 2 agonists was associated with more severe asthma, according to a study published in The Journal of Allergy and Clinical Immunology: In Practice.

Increasing exposure to short-acting beta 2 agonist rescue or reliever medication appeared associated with greater risk for severe asthma exacerbations regardless of inhaled corticosteroid use, according to study results.

Patients with severe asthma experienced decreased exacerbations, hospitalizations, ED visits and corticosteroid exposure 5 years after treatment with bronchial thermoplasty, researchers reported.

Patients with severe asthma saw significant reductions in exacerbations, oral corticosteroid use, exacerbation-related health care resource utilization and medical costs with benralizumab, according to recent research.

PHOENIX — Children with severe asthma appeared more likely to experience NSAID-exacerbated respiratory disease, according to a study presented at the American Academy of Allergy, Asthma & Immunology Annual Meeting.

PHOENIX — Tezepelumab consistently reduced exacerbations in adults and adolescents with severe asthma across all seasons, according to NAVIGATOR trial results presented at the American Academy of Allergy, Asthma & Immunology Annual Meeting.

In a new study, all asthma phenotypes were associated with risk for more severe COVID-19 outcomes, except for type 2 inflammation, researchers reported in the American Journal of Respiratory and Critical Care Medicine.

The Healio Editors compiled the most-read asthma news published in 2021.

The FDA has approved tezepelumab for add-on maintenance treatment of adults and children aged 12 years and older with severe asthma.